Lipoprotein deficiency
Methodology & AI Transparency ⓘ
Lipoprotein deficiency Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as E78.6, Lipoprotein deficiency falls under Cholesterol & Lipids management, where fasting lipid fractionation [Lipoprotein deficiency E78.6] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry E78.6: Lipoprotein deficiency is managed within Cholesterol & Lipids.
- 3 Typical cash cost range: Differential triage of Lipoprotein deficiency (E78.6) utilizes fasting lipid fractionation [Lipoprotein deficiency E78.6].
- 4 Top reported side effects / signs: Follow-up benchmark in Lipoprotein deficiency: maintaining LDL Cholesterol [Lipoprotein deficiency E78.6] within < 85 mg/dL (E78.6).
Ask our AI Specialists anything about Lipoprotein deficiency
What Is Lipoprotein deficiency?
Designated in federal medical registries as E78.6, Lipoprotein deficiency falls under Cholesterol & Lipids management, where fasting lipid fractionation [Lipoprotein deficiency E78.6] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Lipoprotein deficiency (E78.6) features lipoprotein lipase insufficiency [Lipoprotein deficiency E78.6]. therapeutic stabilization in cholesterol & lipids is verified against Fasting Triglycerides [Lipoprotein deficiency E78.6].
Common Symptoms & Clinical Signs
- • Presentation of Lipoprotein deficiency (E78.6): achilles tendon thickening, in Lipoprotein deficiency (E78.6: xanthelasma, or premature)
- • Secondary Lipoprotein deficiency clinical sign: coronary artery calcium [Lipoprotein deficiency E78.6]
- • Symptom flares in Lipoprotein deficiency correlating with LDL Cholesterol [Lipoprotein deficiency E78.6] deviation outside < 85 mg/dL (E78.6)
- • Functional cholesterol & lipids impact requiring fasting lipid fractionation [Lipoprotein deficiency E78.6] evaluation (E78.6)
Lipoprotein deficiency Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E78.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cholesterol, Triglycerides & Lipids | NLM Clinical Tables |
| Diagnostic / Lab Marker: LDL Cholesterol [Lipoprotein deficiency E78.6] | < 85 mg/dL (E78.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Triglycerides [Lipoprotein deficiency E78.6] | < 100 mg/dL (E78.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Lipoprotein(a) [Lp(a)] [Lipoprotein deficiency E78.6] | < 75 nmol/L (E78.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Lipoprotein deficiency
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Pitavastatin Livalo • RxCUI 861643 | HMG-CoA Reductase Inhibitor | 81% | $0.8365 | $ 20.04 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lipoprotein deficiency)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering: What a 2,321-Participant Study Found Factors including statin absence, female sex, diabetes history, ezetimibe use, and a higher high-sensitivity C-reactive protein level may be useful to identify patients who may have a greater LDL-C reduction with BA. Journal of the American Heart Association • 2022-08-02 • Phase III Randomized Trial | N = 2,321 | 96/100 | PMID 35916348 ↗ |
| New Insights on Rosuvastatin versus atorvastatin on small dense low-density: What a 7,802-Participant Study Found Rosuvastatin rather than atorvastatin therapy is likely more effective in reduction of sdLDL levels. Heart and vessels • 2014-05-15 • Meta-Analysis | N = 7,802 | 94/100 | PMID 23644555 ↗ |
| New Insights on Elevated Lipoprotein(a) Predicts Recurrent heart attack in Diabetic Patients: What a 7,887-Participant Study Found Elevated Lp(a) was associated with increased risk of recurrent MI in patients with diabetes after ACS or PCI. Clinical cardiology • 2026-11-15 • Meta-Analysis | N = 7,887 | 94/100 | PMID 42965402 ↗ |
| New Insights on Safety of low lipoprotein(a) levels: the FOURIER: What a 564-Participant Study Found In patients with ASCVD, low Lp(a) concentration was not associated with an increased risk of most adverse safety outcomes, but lower Lp(a) was associated with an increased risk of prevalent and incident DM. European heart journal • 2026-10-26 • Phase III Randomized Trial | N = 564 | 93/100 | PMID 42234492 ↗ |
| Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading? When assessing the effects of escalating cholesterol-lowering therapy, effects upon Pattern B alone to assess coronary heart disease risk may be misleading when interpreted without considerations of other lipid effects, such... Lipids in health and disease • 2010-11-30 • Randomized Controlled Trial | N = 579 | 93/100 | PMID 21118495 ↗ |
Lipoprotein deficiency Patient Community & “People Like Me” Threads
Filter Lipoprotein deficiency community threads and patient logs by age, biological sex, dosage, and treatment duration.